SCHEMBL23057484

SCHEMBL23057484

Cc1nn(N)c2ncnc(N)c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 4/20 0.42
▸ SRC P12931 6/20 0.42
▸ ABL1 P00519 4/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ KDR P35968 3/20 0.42
▸ MTOR P42345 3/20 0.42
▸ HTT P42858 2/20 0.42
▸ LIMK1 P53667 2/20 0.42
▸ RET P07949 2/20 0.42
▸ PLK4 O00444 1/20 0.42
▸ RIPK2 O43353 1/20 0.42
▸ ROCK2 O75116 1/20 0.42
▸ PRKD3 O94806 1/20 0.42
▸ MAP4K4 O95819 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ ERBB2 P04626 1/20 0.42
▸ INSR P06213 1/20 0.42
▸ LCK P06239 1/20 0.42
▸ FYN P06241 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28609414 0.86 NOTUM (0.33) EGFRSRCABL1KDM4EKDR
SCHEMBL10260251 0.80 PIK3CD (0.52) EGFRSRCABL1KDRMTOR
SCHEMBL22748995 0.78 DYRK3 (0.51) EGFRSRCKDRLIMK1RET
SCHEMBL23057505 0.78 EGFR (0.41) EGFRSRCABL1KDM4EKDR
SCHEMBL13019650 0.76 SRC (0.64) EGFRSRCABL1KDM4EKDR
SCHEMBL10261498 0.76 PIK3CD (0.53) EGFRSRCABL1KDM4EKDR
SCHEMBL10261918 0.76 SRC (0.66) EGFRSRCABL1KDRMTOR
SCHEMBL18599138 0.74 EGFR (0.39) EGFRSRCABL1KDM4EKDR
SCHEMBL24096479 0.73 SRC (0.61) EGFRSRCABL1KDRMTOR
SCHEMBL10261070 0.72 SRC (0.52) EGFRSRCABL1KDM4EKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021038540-A1 CYCLOALKYLIDENE CARBOXYLIC ACIDS AND DERIVATIVES AS BTK INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-03-04 — — WO disclosed
Send feedback